O	0	3	The
O	4	12	clinical
O	13	22	relevance
O	23	25	of
B-intervention	26	34	axillary
I-intervention	35	42	reverse
I-intervention	43	50	mapping
I-intervention	51	52	(
I-intervention	52	55	ARM
I-intervention	55	56	)
O	56	57	:
O	58	63	study
O	64	72	protocol
O	73	76	for
O	77	78	a
O	79	89	randomized
O	90	100	controlled
O	101	106	trial
O	106	107	.

O	108	116	Axillary
O	117	122	lymph
O	123	127	node
O	128	138	dissection
O	139	140	(
O	140	144	ALND
O	144	145	)
O	146	148	in
O	149	157	patients
O	158	162	with
O	163	169	breast
O	170	176	cancer
O	177	180	has
O	181	184	the
O	185	194	potential
O	195	197	to
O	198	204	induce
O	205	209	side
O	209	210	-
O	210	217	effects
O	217	218	,
O	219	228	including
O	229	234	upper
O	234	235	-
O	235	239	limb
O	240	250	lymphedema
O	250	251	.

O	252	260	Axillary
O	261	268	reverse
O	269	276	mapping
O	277	278	(
O	278	281	ARM
O	281	282	)
O	283	285	is
O	286	287	a
O	288	297	technique
O	298	302	that
O	303	310	enables
O	311	325	discrimination
O	326	328	of
O	329	332	the
O	333	342	lymphatic
O	343	351	drainage
O	352	354	of
O	355	358	the
O	359	365	breast
O	366	370	from
O	371	375	that
O	376	378	of
O	379	382	the
O	383	388	upper
O	389	393	limb
O	394	396	in
O	397	400	the
O	401	409	axillary
O	410	415	lymph
O	416	420	node
O	421	422	(
O	422	424	LN
O	424	425	)
O	426	431	basin
O	431	432	.

O	433	435	If
O	436	446	lymphedema
O	447	449	is
O	450	456	caused
O	457	459	by
O	460	468	removing
O	469	474	these
O	475	485	lymphatics
O	486	489	and
O	490	495	nodes
O	496	498	in
O	499	502	the
O	503	508	upper
O	509	513	limb
O	513	514	,
O	515	518	the
O	519	530	possibility
O	531	533	of
O	534	545	identifying
O	546	551	these
O	552	562	lymphatics
O	563	568	would
O	569	575	enable
O	576	584	surgeons
O	585	587	to
O	588	596	preserve
O	597	601	them
O	601	602	.

O	603	606	The
O	607	610	aim
O	611	613	of
O	614	618	this
O	619	624	study
O	625	627	is
O	628	630	to
O	631	640	determine
O	641	644	the
O	645	653	clinical
O	654	663	relevance
O	664	666	of
O	667	676	selective
O	677	685	axillary
O	686	688	LN
O	689	692	and
O	693	702	lymphatic
O	703	715	preservation
O	716	718	by
O	719	724	means
O	725	727	of
O	728	731	ARM
O	731	732	.

O	733	735	To
O	736	744	minimize
O	745	748	the
O	749	753	risk
O	754	756	of
O	757	768	overlooking
O	769	774	tumor
O	774	775	-
O	775	783	positive
O	784	787	ARM
O	788	793	nodes
O	794	797	and
O	798	801	the
O	802	812	associated
O	813	817	risk
O	818	820	of
O	821	835	undertreatment
O	835	836	,
O	837	839	we
O	840	844	will
O	845	849	only
O	850	857	include
O	858	866	patients
O	867	871	with
O	872	873	a
O	874	879	tumor
O	879	880	-
O	880	888	positive
O	889	897	sentinel
O	898	903	lymph
O	904	908	node
O	909	910	(
O	910	913	SLN
O	913	914	)
O	914	915	.

O	916	924	Patients
O	925	928	who
O	929	932	are
O	933	943	candidates
O	944	947	for
O	948	952	ALND
O	953	960	because
O	961	963	of
O	964	965	a
O	966	972	proven
O	973	981	positive
O	982	990	axillary
O	991	993	LN
O	994	996	at
O	997	1005	clinical
O	1006	1017	examination
O	1018	1021	can
O	1022	1024	be
O	1025	1033	included
O	1034	1036	in
O	1037	1038	a
O	1039	1051	registration
O	1052	1057	study
O	1057	1058	.

O	1059	1062	The
O	1063	1068	study
O	1069	1073	will
O	1074	1080	enroll
B-total-participants	1081	1084	280
B-eligibility	1085	1093	patients
I-eligibility	1094	1103	diagnosed
I-eligibility	1104	1108	with
I-eligibility	1109	1112	SLN
I-eligibility	1113	1119	biopsy
I-eligibility	1119	1120	-
I-eligibility	1120	1126	proven
I-eligibility	1127	1137	metastasis
I-eligibility	1138	1140	of
I-eligibility	1141	1149	invasive
I-eligibility	1150	1156	breast
I-eligibility	1157	1163	cancer
I-eligibility	1164	1168	with
I-eligibility	1169	1171	an
I-eligibility	1172	1182	indication
I-eligibility	1183	1186	for
I-eligibility	1187	1188	a
I-eligibility	1189	1199	completion
I-eligibility	1200	1204	ALND
O	1204	1205	.

O	1206	1214	Patients
O	1215	1219	will
O	1220	1222	be
O	1223	1233	randomized
O	1234	1236	to
O	1237	1244	undergo
B-control	1245	1253	standard
I-control	1254	1258	ALND
O	1259	1261	or
O	1262	1264	an
O	1265	1269	ALND
O	1270	1272	in
O	1273	1278	which
O	1279	1282	the
O	1283	1286	ARM
O	1287	1292	nodes
O	1293	1296	and
O	1297	1302	their
O	1303	1316	corresponding
O	1317	1327	lymphatics
O	1328	1332	will
O	1333	1335	be
O	1336	1340	left
O	1341	1343	in
O	1344	1348	situ
O	1348	1349	.

O	1350	1357	Primary
O	1358	1365	outcome
O	1366	1368	is
O	1369	1372	the
B-outcome-Measure	1373	1381	presence
I-outcome-Measure	1382	1384	of
I-outcome-Measure	1385	1393	axillary
I-outcome-Measure	1394	1401	surgery
I-outcome-Measure	1401	1402	-
I-outcome-Measure	1402	1409	related
I-outcome-Measure	1410	1420	lymphedema
O	1421	1423	at
O	1424	1425	6
O	1425	1426	,
O	1427	1429	12
O	1429	1430	,
O	1431	1434	and
O	1435	1437	24
O	1438	1444	months
O	1445	1449	post
O	1449	1450	-
O	1450	1461	operatively
O	1461	1462	,
O	1463	1471	measured
O	1472	1474	by
O	1475	1478	the
O	1479	1484	water
O	1484	1485	-
O	1485	1497	displacement
O	1498	1504	method
O	1504	1505	.

O	1506	1515	Secondary
O	1516	1523	outcome
O	1524	1532	measures
O	1533	1540	include
B-outcome-Measure	1541	1545	pain
O	1545	1546	,
B-outcome-Measure	1547	1558	paresthesia
O	1558	1559	,
B-outcome-Measure	1560	1568	numbness
O	1568	1569	,
O	1570	1573	and
B-outcome-Measure	1574	1578	loss
I-outcome-Measure	1579	1581	of
I-outcome-Measure	1582	1590	shoulder
I-outcome-Measure	1591	1599	mobility
O	1599	1600	,
B-outcome-Measure	1601	1608	quality
I-outcome-Measure	1609	1611	of
I-outcome-Measure	1612	1616	life
O	1616	1617	,
O	1618	1621	and
B-outcome-Measure	1622	1630	axillary
I-outcome-Measure	1631	1641	recurrence
I-outcome-Measure	1642	1646	risk
O	1646	1647	.

O	1648	1651	The
O	1652	1659	benefit
O	1660	1662	of
O	1663	1667	ALND
O	1668	1670	in
O	1671	1679	patients
O	1680	1684	with
O	1685	1686	a
O	1687	1695	positive
O	1696	1699	SLN
O	1700	1702	is
O	1703	1704	a
O	1705	1712	subject
O	1713	1715	of
O	1716	1722	debate
O	1722	1723	.

O	1724	1727	For
O	1728	1732	many
O	1733	1741	patients
O	1741	1742	,
O	1743	1745	an
O	1746	1750	ALND
O	1751	1755	will
O	1756	1762	remain
O	1763	1766	the
O	1767	1776	treatment
O	1777	1779	of
O	1780	1786	choice
O	1786	1787	.

O	1788	1792	This
O	1793	1804	multicenter
O	1805	1815	randomized
O	1816	1821	trial
O	1822	1826	will
O	1827	1834	provide
O	1835	1843	evidence
O	1844	1846	of
O	1847	1854	whether
O	1855	1857	or
O	1858	1861	not
O	1862	1870	axillary
O	1871	1873	LN
O	1874	1886	preservation
O	1887	1889	by
O	1890	1895	means
O	1896	1898	of
O	1899	1902	ARM
O	1903	1912	decreases
O	1913	1916	the
O	1917	1921	side
O	1921	1922	-
O	1922	1929	effects
O	1930	1932	of
O	1933	1935	an
O	1936	1940	ALND
O	1940	1941	.

O	1942	1951	Enrolment
O	1952	1954	of
O	1955	1963	patients
O	1964	1968	will
O	1969	1974	start
O	1975	1977	in
O	1978	1983	April
O	1984	1988	2013
O	1989	1991	in
O	1992	1996	five
O	1997	2003	breast
O	2003	2004	-
O	2004	2010	cancer
O	2011	2018	centers
O	2019	2021	in
O	2022	2025	the
B-location	2026	2037	Netherlands
O	2037	2038	,
O	2039	2042	and
O	2043	2045	is
O	2046	2054	expected
O	2055	2057	to
O	2058	2066	conclude
O	2067	2069	by
O	2070	2075	April
O	2076	2080	2016
O	2080	2081	.

O	2082	2088	TC3698
O	2088	2089	.
